Here are the 10-K annual reports from Atea Pharmaceuticals, Inc. (AVIR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AVIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVIR filings page.
Atea Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company developing novel oral antivirals for serious viral diseases. Its lead program is a fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV), positioned as a short-duration, pan‑genotypic, protease inhibitor‑free regimen.
Atea is running two large global Phase 3 trials, C‑BEYOND in the US/Canada and C‑FORWARD outside North America, each targeting about 880 treatment‑naïve HCV patients with and without compensated cirrhosis. C‑BEYOND is fully enrolled, with topline results expected mid‑2026, and C‑FORWARD topline data targeted for year‑end 2026, followed by a planned US NDA submission in March 2027.
The company is also advancing AT‑587, a nucleotide prodrug for chronic hepatitis E virus (HEV), with a first‑in‑human Phase 1 study planned for mid‑2026. Atea licenses ruzasvir from Merck under a global agreement that included a $25.0 million upfront payment, up to $135.0 million in development and regulatory milestones, up to $300.0 million in sales milestones, and tiered royalties from high single‑digit to mid‑teens percentages. Atea previously discontinued development of bemnifosbuvir for COVID‑19 after the Phase 3 SUNRISE‑3 trial did not meet its primary endpoint.